NDAORALSUSPENSION
Approved
Aug 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Triple Sulfas is a fixed-dose combination of three sulfonamide antibiotics (sulfadiazine, sulfamerazine, and sulfamethazine) approved in 1949 for oral suspension. This product represents an older generation of broad-spectrum antimicrobials used historically for bacterial infections. The combination formulation provides synergistic antimicrobial coverage through multiple sulfonamide mechanisms.
LOE Approaching
With LOE approaching and minimal linked job activity, this product faces significant commercial wind-down; any remaining roles are likely legacy support or specialized clinical affairs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers linked to Triple Sulfas are extremely limited due to its approaching loss of exclusivity and minimal commercial activity. Roles that do exist focus on compliance, supply chain, and legacy product stewardship rather than growth or innovation.
Regulatory Affairs Specialist (legacy compliance)Pharmacovigilance Associate (monitoring)
Worked on TRIPLE SULFAS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.